Hologic divests drug
This article was originally published in The Gray Sheet
Executive Summary
Women's health device maker divests Gestiva, its "non-core" drug for the prevention of preterm birth, to KV Pharmaceutical for $82 million in a deal announced Jan. 22. The drug, which is pending FDA approval, was part of Hologic's October purchase of cervical cancer test firm Cytyc (1"The Gray Sheet" May 28, 2007, p. 10)
You may also be interested in...
Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.